StockData

Liminatus Pharma, Inc. (LIMN) stock

LIMNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as LIMNW
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 2/30
$2.81−0.16 (-5.39%)

Close on Nov 17, 2026Market cap $188.72MP/E –Yield –

Liminatus Pharma price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

No price to sales ratio figures for Liminatus Pharma

Liminatus Pharma has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Liminatus Pharma figures

See a number that looks wrong?